Arsene Mekinian/X
Dec 24, 2025, 05:57
Arsene Mekinian Shares a Concise Update: The Evolving Understanding of PR PID
Arsene Mekinian, Professor of Medicine at Sorbonne University, President of Santé Arménie, posted on LinkedIn:
“PR PID
No unequivocal definition but any manifestation, including asymptomatic pulmonary
Significant mortality
No screening except for clinical signs
Genetic marker MUC5B
Dogma not TNFi would be invalidated by a recent study”
Follow the latest in Hemostasis Today.
-
Aug 15, 2026, 19:30José Luis Neyro: E4 and DRSP Reduce Hirsutism While Showing Comparable Effects on Thrombin Generation
-
Aug 15, 2026, 19:27Mahmoud Akraym: Don’t Choose Anticoagulation as the Immediate Treatment for Unstable AF
-
Aug 15, 2026, 19:25Ahmed Bennis: DOACs Increase 1-Year Stroke Risk but Reduce MI Risk Compared With Warfarin
-
Aug 15, 2026, 19:24Megan Adediran: An Unwavering Fight for People Living With Haemophilia
-
Aug 15, 2026, 19:23Intravenous Anticoagulation Linked to Worse Early Outcomes After Noncardioembolic Stroke – International Journal of Stroke
-
Aug 15, 2026, 18:03Alejandro González Veliz: Pulmonary Embolism Is Not Always an Anticoagulation-Only Problem
-
Aug 15, 2026, 17:57Ayesha Zia: A New Foundation for Pediatric Pulmonary Embolism Research and Care
-
Aug 15, 2026, 17:50Muhammad Shaheer Bin Faheem: 25 Years of Thromboembolism and Hypertension Mortality
-
Aug 15, 2026, 17:21Bilal Salman։ NETosis as a Therapeutic Target in Inflammation and Thrombosis